| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/29/2009 | US7638545 Anthelmintic composition |
| 12/29/2009 | US7638511 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
| 12/29/2009 | US7638507 Compositions for treatment of inflammatory diseases |
| 12/29/2009 | US7638502 Treatment of EBV and KHSV infection and associated abnormal cellular proliferation |
| 12/29/2009 | US7638501 Administering of pyrimidine-based nucleoside such as triacetyluridine; dihydroorotate dehydrogenase and uridine monophosphate synthetase inhibitors |
| 12/29/2009 | US7638497 For enhancing apoptosis and treating proliferative disorders; antitumor agents |
| 12/29/2009 | US7638492 Using programmed death-1 (PD-1) protein as evaluative tool to identify modulators for treatment and prevention of nervous system, autoimmune, cell proliferative and allergic disorders |
| 12/29/2009 | US7638480 Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
| 12/29/2009 | US7638283 Amyloid β protein (globular assembly and uses thereof) |
| 12/29/2009 | US7638272 administering a polypeptide to the cancer cells of the mammal in vivo for sensitizing the cancer cells to the therapeutic chemotherapy, radiation treatment; gene expressed polypeptide; secreted protein acidic and rich in cystein |
| 12/29/2009 | US7638269 Viral capsid assembly intermediates and methods of production |
| 12/29/2009 | CA2464768C Method and composition for potentiating an opiate analgesic |
| 12/29/2009 | CA2447521C Delivery of antihistamines through an inhalation route |
| 12/29/2009 | CA2428511C Novel uses of combined 5-ht1a agonists and serotonin reuptake inhibitors |
| 12/29/2009 | CA2428133C Indolylmaleimide derivatives as protein kinase c inhibitors |
| 12/29/2009 | CA2425215C Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 12/29/2009 | CA2424797C Methods of inducing cancer cell death and tumor regression |
| 12/29/2009 | CA2411058C Skin treatment using a new retinoid |
| 12/29/2009 | CA2338543C Method of direct identification of compound efficacy at a g protein-coupled orphan receptor |
| 12/24/2009 | US20090318463 Indolylmaleimide Derivatives |
| 12/24/2009 | US20090318390 Combinations comprising epothilones and pharmaceutical uses thereof |
| 12/24/2009 | US20090318357 Molecules Preferentially Associated with Effector T Cells or Regulatory T Cells and Methods of Their Use |
| 12/24/2009 | US20090318352 Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins |
| 12/24/2009 | US20090317538 Biologically active implants |
| 12/24/2009 | US20090317410 Use of zwitterionic polysaccharides for the specific modulation of immune processes |
| 12/24/2009 | US20090317403 Use of CSF-1 Inhibitors |
| 12/24/2009 | US20090317364 Novel compositions for prevention and treatment of mastitis and metritis |
| 12/24/2009 | US20090317354 Composition for restoring damaged skin comprising a saccaride and povidone-iodine |
| 12/23/2009 | WO2009155135A1 Composition comprising liposome-entrapped doxorubicin and methods of admnistration for treatment of multiple myeloma |
| 12/23/2009 | WO2009154944A2 Pharmaceutical formulations and methods of use which combine non-steroidal anti-inflammatory compounds with anti-hypertensive compounds |
| 12/23/2009 | WO2009154573A1 Modulators of stat3 signalling |
| 12/23/2009 | WO2009154264A1 Peptide |
| 12/23/2009 | WO2009154237A1 Stabilizer for lymph vessel |
| 12/23/2009 | WO2009154148A1 Analgesic anti-inflammatory preparation for external application |
| 12/23/2009 | WO2009153791A1 Antiviral terpenoid compounds |
| 12/23/2009 | WO2009153291A1 Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders |
| 12/23/2009 | WO2009133470A3 Use of dronedarone alone or in combination for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level |
| 12/23/2009 | WO2009133310A3 Combination of dronedarone with at least one diuretic, and therapeutic use thereof |
| 12/23/2009 | WO2009111739A3 Treatment of herpes virus related diseases |
| 12/23/2009 | WO2009074969A3 Spingosine-1-phosphate, analogues and antagonists for use as medicaments |
| 12/23/2009 | WO2009020534A3 Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines |
| 12/23/2009 | WO2008091643A3 Evaluating synergy of combinations comprising an antibody in immune suppressive pathways concurrent to immunotherapy |
| 12/23/2009 | WO2008083204A3 Modulation of neurogenesis by melatoninergic ligands |
| 12/23/2009 | WO2000015247A8 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| 12/23/2009 | EP2135622A2 Compositions for providing an analgesic effect to the skin |
| 12/23/2009 | EP2135621A1 Combined formulations for the treatment of the male infertility |
| 12/23/2009 | EP2135620A1 Ocular hypotensive agent comprising compound capable of inhibiting histone deacetylase as active ingredient |
| 12/23/2009 | EP2135617A2 Amylin and amylin agonists for treating psychiatric diseases and disorders |
| 12/23/2009 | EP2135609A1 Combinations of nicotinic acetylcholine alpha 7 receptor agonists |
| 12/23/2009 | EP2135607A1 Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| 12/23/2009 | EP2135603A2 Compositions and methods for increasing insulin sensitivity |
| 12/23/2009 | EP2135600A1 Targeting agent for cancer cell or cancer-associated fibroblast |
| 12/23/2009 | EP2134368A1 Homeopathic medicament useful for immunomodulation |
| 12/23/2009 | EP1709037B1 Hiv protease inhibiting sulfonamides |
| 12/23/2009 | EP1613302B1 Preserved and stable compositions containing peptide copper complexes and methods related thereto |
| 12/23/2009 | EP1534390B1 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene hydrazino -2'-hydroxy- 1,1'-biphenyl -3-carboxylic acid bis-(monoethanolamine) |
| 12/23/2009 | EP1483251B1 C3-cyano epothilone derivatives |
| 12/23/2009 | EP1421174B1 Hematopoietic cell e-selectin/l-selectin ligand polypeptides and methods of use thereof |
| 12/23/2009 | EP1341538B1 Medicament compositions with salts of tiotropium and epinastin for the therapy of respiratory diseases |
| 12/23/2009 | EP1312259B1 Type iii allergic inflammation model animal |
| 12/23/2009 | EP1296972B1 Arylmethylamine derivatives for use as tryptase inhibitors |
| 12/23/2009 | EP1274861B1 Compositions and methods for identifying and targeting cancer cells |
| 12/23/2009 | CN101610790A Novel compositions and uses thereof |
| 12/23/2009 | CN101610789A Methods, compositions, and kits for treating pain and pruritis |
| 12/23/2009 | CN101610776A Combination comprising CNDAC (2'-cyano-2'-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent |
| 12/23/2009 | CN101610765A New combination for use in the treatment of inflammatory disorders |
| 12/23/2009 | CN101610754A Pharmaceutical composition containing fine particle oil-based suspension |
| 12/23/2009 | CN101607087A Combinations of dmxaa and other anti-cancer agents |
| 12/23/2009 | CN101607086A Compound bismuth composition and preparation method thereof |
| 12/23/2009 | CN100572363C New imidazole derivative, method for producing the same and use of the same |
| 12/23/2009 | CN100571777C Composition containing ADP receptor antagonist and nitrate medicine |
| 12/23/2009 | CN100571776C Association between a PPAR ligand and an antioxidant agent and use thereof for treating obesity |
| 12/23/2009 | CN100571695C Bilayer pharmaceutical tablets comprising telmisartan and diuretic and their preparation |
| 12/23/2009 | CN100571688C Medicine-loading sustained-release micro-capsule and preparing method thereof |
| 12/23/2009 | CA2727155A1 Anti-inflammatory analgesic external preparation |
| 12/23/2009 | CA2727064A1 Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders |
| 12/23/2009 | CA2726337A1 Pharmaceutical formulations and methods of use which combine non-steroidal anti-inflammatory compounds with anti-hypertensive compounds |
| 12/22/2009 | US7635774 Benzimidazole derivatives |
| 12/22/2009 | US7635757 Nucleotide sequence which hybridizes to the complement of the specific nucleic acid molecule over its full length under conditions of incubation and encodes a polypeptide which costimulates T cell proliferation in vitro |
| 12/22/2009 | US7635713 Preterm labor, dysmenorrhea, asthma, hypertension, infertility, sexual disorders, undesired blood clotting, bone disorders, eclampsia, or eosinophil disorder; use in combination with a phosphodiesterase inhibitor; e.g. (5Z)-7-{1-[3-hydroxy-4-(3-methylphenyl)butyl]-3-oxopyrrolidin-2-yl}hept-5-enoic acid |
| 12/22/2009 | US7635708 Peroxidase proliferator activated receptor (PPAR) gamma agonists for playing key role in inducing growth arrest by terminal differentiation of actively proliferating PPAR gamma-expressing cells, particularly transformed adipose cells |
| 12/22/2009 | US7635686 Cancer treatment with a synthetic sequences |
| 12/22/2009 | US7635684 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 12/22/2009 | US7635674 insulin and carrieres, a second pharmaceutical composition containing O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime ( BGP-15) and carriers; prediabetic state, metabolic X-syndrome, insulin sensitivity, glucose tolerance, dislipidemia or diabetes mellitus |
| 12/22/2009 | US7635556 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 12/22/2009 | US7635486 Where lipidation thereof is from expression of first nucleic acid sequence and protein portion thereof is from expression of second nucleic acid sequence and first and second sequences do not naturally occur together, such as a lipoprotein where first sequence encodes Borrelia lipoprotein, second, PsaA |
| 12/22/2009 | US7635481 Ehrlichia canis bacterin, a carrier, an antibody response inducing agent and a cell-mediated immunity response inducing agent |
| 12/22/2009 | CA2627862C Use of inhibitors of dipeptidyl peptidase iv (dp iv) in combination with inhibitors of alanyl-aminopeptidase (apn) |
| 12/22/2009 | CA2523734C Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients |
| 12/22/2009 | CA2482447C Dual dispenser for aesthetically acceptable delivery of anhydrous skin treatment compositions |
| 12/22/2009 | CA2462369C Compositions for delivery of drug combinations |
| 12/22/2009 | CA2461248C Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| 12/22/2009 | CA2452558C A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| 12/22/2009 | CA2451106C Sequential drug delivery systems |
| 12/22/2009 | CA2447166C Delivery of erectile dysfunction drugs through an inhalation route |
| 12/22/2009 | CA2446990C Delivery of sedative-hypnotics through an inhalation route |
| 12/22/2009 | CA2446917C Delivery of antipsychotics through an inhalation route |
| 12/22/2009 | CA2446916C Delivery of opioids through an inhalation route |
| 12/22/2009 | CA2427301C Method for the preparation of a pharmaceutical composition, and its use |
| 12/22/2009 | CA2426210C Treatment of pcp addiction and pcp addiction-related behavior |